Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CoviVac
- Development stage
- Unknown
- Lead developer
- Chumakov Federal Scientific Center
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CoviVac is an inactivated whole-virion vaccine developed by the Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products to prevent COVID-19. The vaccine is produced by cultivating the SARS-CoV-2 strain AYDAR-1 in Vero cells, followed by inactivation with beta-propiolactone and purification. It is formulated with aluminum hydroxide as an adjuvant. Unlike mRNA or viral vector vaccines that focus primarily on the spike protein, CoviVac presents the entire inactivated virus to the immune system, potentially inducing a broader immune response against multiple viral structural proteins, including the nucleocapsid, envelope, and membrane proteins. It is typically administered as a two-dose intramuscular regimen and is notable for its stability at standard refrigeration temperatures (2-8°C), facilitating easier distribution compared to ultra-cold chain vaccines.
- Brand names
- CoviVacKoviVac
- Other names
- Inactivated whole-virion concentrated purified coronavirus vaccineChumakov COVID-19 vaccineChumakov vaccine
Beyond the preview
Go deeper on CoviVac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoviVac.